Skip to content
Screener

Mannkind MNKD Liability Sale Of Future Royalties Non Current

Liability Sale Of Future Royalties Non Current at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$305.04M+22.9%
Regenxbio logo
RegenxbioRGNX
$42.56M+10.2%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.02B+9.3%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%
Geron logo
GeronGERN
$20.69M+18.6%
Geron logo
GeronGERN
$20.69M+18.6%

Other financials

Income statement

See full
Revenue$109.4M+42.9%
Gross profit$95.0M+32.0%
Operating income-$350.0K-107%
Net income-$19.0M-2,949%
EPS (diluted)-$0.06

Balance sheet

See full
Cash & equivalents$52.9M-7.2%
Total debt$11.8M-7.5%
Total equity-$67.2M-22.1%
Total assets$732.3M+77.9%

Cash flow

See full
Operating cash flow-$18.4M-305%
CapEx$5.1M+355%
Free cash flow-$23.5M-399%

Valuation

See full
Market cap$1.25B+17.8%
Enterprise value$1.21B+18.9%
P/S3.2×-0.3×

Profitability

See full
Gross margin89.8%-4.8pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity44.2%
Debt / equity-0.2×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:LiabilitySaleOfFutureRoyaltiesNonCurrent.

The source filing: Mannkind’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335054
Line itemJune 30, 2026December 31, 2025
Deferred revenue – current11,08515,331
Recognized loss on purchase commitments – current1,210
Total current liabilities142,898171,031
Liability for sale of future royalties – long term133,552136,985
Financing liability – long term92,49793,092
Deferred revenue – long term36,85739,977
Recognized loss on purchase commitments – long term62,92265,952
Operating lease liability9,68710,689

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Mannkind's liability sale of future royalties non current?
Mannkind (MNKD) reported liability sale of future royalties non current of $133.55M in Q2 2026.
How has Mannkind's liability sale of future royalties non current changed year-over-year?
Mannkind's liability sale of future royalties non current decreased by 2.7% year-over-year, from $137.23M to $133.55M.
What is the long-term trend for Mannkind's liability sale of future royalties non current?
Over 2 years (2023 to 2025), Mannkind's liability sale of future royalties non current has grown at a 0.3% compound annual growth rate (CAGR), from $136.05M to $136.99M.
What does liability sale of future royalties non current mean?
Liability Sale Of Future Royalties Non Current as reported by Mannkind Corporation.

Ask your AI about Mannkind's liability sale of future royalties non current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude